Stock Analysis

Why DBV Technologies S.A. (EPA:DBV) Could Be Your Next Investment

DBV Technologies S.A. (EPA:DBV) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case of DBV, it is a company with strong financial health as well as a buoyant growth outlook. Below is a brief commentary on these key aspects. If you're interested in understanding beyond my broad commentary, read the full report on DBV Technologies here.

Flawless balance sheet with high growth potential

DBV is an attractive stock for growth-seeking investors, with an expected earnings growth of 33% in the upcoming year. The optimistic bottom-line growth is supported by a similarly outstanding revenue growth over the same time period, which indicates that earnings is driven by top-line activity rather than purely unsustainable cost-reduction initiatives. DBV's strong financial health means that all of its upcoming liability payments are able to be met by its current cash and short-term investment holdings. This indicates that DBV has sufficient cash flows and proper cash management in place, which is a key determinant of the company’s health. With a debt-to-equity ratio of 1.8%, DBV’s debt level is relatively low. DBV has plenty of financial flexibility, without large debt obligations to meet in the short term, as well as the headroom to raise debt should it need to in the future.

ENXTPA:DBV Past and Future Earnings, March 12th 2019
ENXTPA:DBV Past and Future Earnings, March 12th 2019

Next Steps:

For DBV Technologies, I've compiled three key aspects you should further examine:

  1. Historical Performance: What has DBV's returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
  2. Valuation: What is DBV worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether DBV is currently mispriced by the market.
  3. Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of DBV? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About ENXTPA:DBV

DBV Technologies

A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.

Adequate balance sheet with slight risk.

Weekly Picks

AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25268.7% overvalued
32 users have followed this narrative
0 users have commented on this narrative
13 users have liked this narrative
AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.5% undervalued
40 users have followed this narrative
7 users have commented on this narrative
14 users have liked this narrative
FU
FundamentallySarcastic
CCP logo
FundamentallySarcastic on Credit Corp Group ·

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Fair Value:AU$12.6412.1% overvalued
7 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Updated Narratives

JE
JeremyBeeAi
PSEC logo
JeremyBeeAi on Prospect Capital ·

Title: Market Sentiment Is Dead Wrong — Here's Why PSEC Deserves a Second Look

Fair Value:US$3.8934.4% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
davidlsander
QS logo
davidlsander on QuantumScape ·

An amazing opportunity to potentially get a 100 bagger

Fair Value:US$2555.9% undervalued
132 users have followed this narrative
10 users have commented on this narrative
0 users have liked this narrative
YI
AMZN logo
yiannisz on Amazon.com ·

Amazon: Why the World’s Biggest Platform Still Runs on Invisible Economics

Fair Value:US$231.382.0% undervalued
6 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8686.7% undervalued
82 users have followed this narrative
8 users have commented on this narrative
23 users have liked this narrative
TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.5% undervalued
124 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3930.5% undervalued
975 users have followed this narrative
6 users have commented on this narrative
26 users have liked this narrative